Evidence map›Paper›PMID 42602129›Full record

ArticleFrontiers in immunology2026

Vertebral body dosimetry associated with hematologic toxicities and survival in esophageal squamous-cell carcinoma treated with chemoradiotherapy plus immunotherapy.

Shijie Shang, Qian Song, Xinyi Liang, Shan Yin, Zijun Zhai, Shuling Ma, Xinpei Li, Haonan Xiao, Jingxin Zhang, Jinming Yu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shijie ShangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Qian SongShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xinyi LiangShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Shan YinShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Zijun ZhaiShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Shuling MaShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xinpei LiShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Haonan XiaoDepartment of Radiation Oncology and Physics, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Jingxin ZhangShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Jinming YuShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Jiachun MaShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
Xiaorong DongCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Dawei ChenShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The addition of immunotherapy to definitive chemoradiotherapy has improved outcomes for patients with unresectable advanced esophageal squamous-cell carcinoma (ESCC). However, treatment-related hematologic toxicity, particularly radiation-induced lymphopenia, may impair systemic antitumor immunity and compromise the efficacy of immunotherapy. Because vertebral bodies (VB) contain a substantial proportion of active bone marrow, irradiation of this region may contribute to immune cell depletion. This study evaluated the association between VB dose-volume parameters and grade ≥3 hematologic toxicities (HT3+) in ESCC patients treated with chemoradiotherapy and immunotherapy. Methods: All radiation doses were converted to equivalent doses in 2 Gy fractions (EQD Results: Among 157 ESCC patients, 141 (89.8%) developed HT3 +. Low-dose VB irradiation parameters (V5 Conclusions: Low-dose VB irradiation is strongly associated with severe hematologic toxicity in ESCC patients receiving chemoradiotherapy and immunotherapy. Minimizing VB exposure during treatment planning may help preserve lymphocyte counts, mitigate radiation-induced immune suppression, and support immune-mediated treatment efficacy.

Indexed as

ChemoradiotherapyEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaImmunotherapySpineAdultAgedFemaleHumansLymphopeniaMaleMiddle AgedRadiometryTreatment Outcomeesophageal squamous-cell carcinomaimmunotherapylymphopeniaradiotherapysurvivalvertebral body dosimetry

Identifiers

PMID42602129
PMCPMC13473295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.